Aventis refuses to yield to Sanofi: CEO dismisses hope for a friendly deal, plans asset split-off

Article Abstract:

Aventis SA dismissed the possibility of a merger with rival drugmaker Sanofi Synthelabo SA, and persuaded the shareholders not to entertain a hostile takeover offer from Sanofi. Sanofi-Synthelabo SA announced plans to split off underperforming assets and provided a forecast for stronger sales growth in coming years.

Pharmaceutical preparations, Sanofi-Synthelabo S.A., SASY

---

Alnylam, Ribopharma to merge

Article Abstract:

Alnylam Pharmaceuticals Inc. is expected to merge with Ribopharma AG. The merged entity will use RNA interference techniques to develop new drugs.

United States, Germany, Biotechnology industry, Biotechnology industries, Alnylam Pharmaceuticals Inc., Ribopharma AG

---

Aventis said "non" to Sanofi, so now it has to get tough

Article Abstract:

Aventis SA's board rejected a 46 billion Euro hostile takeover bid by pharmaceutical competitor Sanofi-Synthelabo SA.

Strategy & planning, Planning, Sanofi S.A., Company business planning

Similar abstracts:

• Abstracts: German banks pressed to combine. Banques Populaires, DZ Bank unveil plans to join forces. Caisse des Depots will rebuild alliance with big savings bank
• Abstracts: Alitalia plan to raise capital could run into difficulties. Alitalia plans wide sale talks. Balmain makes bid for Mugler couture
• Abstracts: European Commission is set to approve rescue of Alitalia. Emissions-trading law passes. Airline passengers bumped in Europe may get cash
• Abstracts: Fed raises interest-rate target for 5th time this year, to 2.25%. Deflation risks may force Federal Reserve to cut rates
• Abstracts: No going back. Afghanistan hopes for neighbourly goodwill

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.